Latest Content

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how manufacturers can build the talent and support structures required to keep the US drug supply safe and accessible.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

Counterfeit pharma networks are becoming more sophisticated—leveraging advanced packaging, fragmented logistics, and global trade gaps—making detection harder and patient risk greater than ever.

Rising prescription costs and premiums are forcing more than half of patients to take drastic measures to cover OOP costs.

Various agreements with the Trump administration could have long-term ramifications for Medicaid access and global pricing strategy.

As the FDA ends its phased exemption period for most trading partners, Two Labs’ Michael Rowe warns that DSCSA compliance is entering a far more complex era—one shaped by real-time traceability, digital record requirements, and a transition to a 12-digit NDC.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses how the convergence of patient access services with traditional distribution models is setting the stage for medically integrated dispensing to expand beyond oncology.

In today’s Pharma Pulse, Augmentin XR is the first drug approved under the FDA's new CNPV pilot program and much more.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, highlights how two decades of commercial trade and distribution have transformed the channel from a primarily supply-chain-focused function into a more integrated discipline.

In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.

Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.

In the final part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, explains how amid soaring patient and provider frustration, new HTI-4 standards are rapidly forcing change across the insurance and technology sectors to solve the current "transparency problem," making the status of a life-saving prescription as clear and actionable as tracking a takeout order.

In today’s Pharma Pulse, new trials confirm AI chatbots are a successful and sustainable tool for increasing pneumococcal vaccine uptake among older adults and much more.